VJHemOnc Podcast

Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and chronic forms. Novel approaches are being explored to minimize the risk of GvHD and improve the overall success of alloSCT.

In this podcast, you will hear from experts Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Christopher Kanakry, MD, National Cancer Institute, Bethesda, MD, who discuss the importance of addressing post-transplant complications, and further highlight current approaches to GvHD prophylaxis and treatment.

Over the last two decades, treatment approaches for multiple myeloma have significantly changed, and measurable residual disease (MRD) assessment is being increasingly recognized as a valuable tool to monitor patient response to therapy. Although there are several clinical trials incorporating MRD status as a clinical endpoint, its use in the real-world setting remains unclear.

In this podcast, you will hear from experts Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Mattia D’Agostino, MD, University of Turin, Turin, Italy, and Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who discuss the prognostic role of MRD in multiple myeloma, the value of MRD-guided treatment, and clinical trials in this space. 

Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are being explored for the treatment of patients, especially those with relapsed/refractory (R/R) or high-risk disease. Immune therapies including CAR-T therapy and monoclonal antibodies are a promising option for patients, and are being evaluated in MDS following their success in other hematological malignancies. However, several challenges need to be addressed before these can be applied in clinical practice.

In this podcast, you will hear from experts David Sallman, MD, Moffit Cancer Center, Tampa, FL, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, who discuss novel immune therapies being explored in MDS, emphasizing the challenges and opportunities for CAR-T therapy in this space.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, and Tycel Phillips, MD, City of Hope, Duarte, CA, who share their highlights in non-Hodgkin lymphoma (NHL). Topics covered include updates from the TRIANGLE trial (NCT02858258), the changing role of transplantation, and novel immunotherapies in the field.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, and Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in myeloproliferative neoplasms (MPNs) presented at this year's meeting. Topics covered include updates from the MOMENTUM trial (NCT04173494), the importance of combination approaches, and novel agents being explored, including calreticulin (CALR)-targeting antibodies. 

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Kate Cwynarski, FRCP, FRCPath, PhD, University College Hospitals London NHS Foundation Trust, London, UK, and Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in T-cell lymphoma. Topics covered include the importance of real-world data (RWD) in this space, addressing CNS relapse, and novel treatment approaches being explored.

CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role in a variety of hematological malignancies, including acute myeloid leukemia (AML), lymphoma, and myelodysplastic syndromes (MDS). Currently, several anti-CD47 agents are under investigation for MDS, with promising results being demonstrated in clinical trials. 

In this exclusive podcast, you will hear from Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, and David Sallman, MD, Moffit Cancer Center, Tampa, FL, who discuss the important role of CD47 in MDS, agents under investigation, and other targets of interest in this space. 

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who discuss recent updates in chronic lymphocytic leukemia (CLL). The experts comment on the role of doublet and triplet therapies in CLL, clinical trial updates, and further highlight the impact of novel Bruton's tyrosine kinase (BTK) inhibitors in this space.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies. 

In this podcast, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss key updates in myelodysplastic syndromes (MDS) presented at this year's meeting. Topics covered include the treatment of lower-risk and higher-risk disease, novel classification systems, clinical trial updates, and treatment options after failure to hypomethylating agents (HMAs).